胃癌Her-2的表达与靶向治疗

摘要

The incidence of gastric cancer is in the fourth place of all cancers in worldwide ,and the fatal-ity rate is in the second place .Standard chemotherapy regimens play an important role in prolonging gastric cancer survival rate.However,most of gastric cancers are in advanced stage when diagnose is finally made .The current medical practice can only meet the limited treatment options .In the last several decades ,study of the molecular mechanisms of gastric cancer gets constant new progress .By inhibiting the human epidermal growth factor receptor 2(Her-2)for advanced gastric cancer,it provides a new treatment for patients.Trastuzumab is a kind of Her -2 monoclonal antibody .It is the first kind of targeted therapy drug for the treatment of metastatic gastric cancer .A combination of trastuzumab with cisplatin and 5-fluorouracil based chemotherapy benefits gastric cancer overall survival.Overexpression of Her -2 provides evidence for the targeted therapy .So we reviewed Her -2 excessive expression of gastric carcinoma in recent years and represented by bead sheet resistance to targeted therapy .In this paper ,research of overpression of Her -2 and targeted threrapy in gastric cancer are summarized .%胃癌在的全球范围内的发病率居癌症第四位，致死率居癌症第二位。标准的化学治疗方案在延长胃癌生存时间方面发挥了重要的作用。但由于多数胃癌在确诊时已处在进展期，因此当前的医学实践只能满足有限的治疗选择。在过去几十年中，关于胃癌发生的分子机制的研究不断获得新进展。通过靶向抑制人类表皮生长因子受体2（Her-2）来治疗进展期胃癌，为患者提供了新的治疗方案。曲妥珠单抗，是一种Her-2单克隆抗体，是第一种治疗转移性胃癌的靶向药物，它与以顺铂及5-氟尿嘧啶为基础的化学治疗的联合应用，可以使胃癌整体生存获益。而Her-2过度表达为靶向治疗提供了证据。因此，本文就近年来关于胃癌Her-2过度表达和胃癌的靶向治疗做一综述。